drugset / Trial / NCT07136805

A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis

NCT07136805

Phase 3 Not yet recruiting 152 enrolled VivaVision Biotech, Inc
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a multicenter, randomized, single-masked, active-controlled, parallel, Phase III pivotal study in China

Timeline

Start
2025-10-01
Primary completion
2026-12-31
Completion
2027-04-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Prednisolone Other / unclassified 1 % Other
Subject VVN461 Unknown 1 % Other